Drugs › Topoisomerase inhibitor
Brand name · Etoposide
VePesid: adverse event reports filed with FDA
900 reports list it as a suspect or interacting product, 2004–2026. Class: Topoisomerase inhibitor.
- 900
- reports as suspect product
- 0% of all reports · about 40 a year
- 20
- reports, 12 months to June 2026
- 14 in the 12 months before
- 96.7%
- marked serious by the reporter
- 96.8% across the class
- 23.1%
- record death among outcomes, as reported
- 208 reports · not verified by FDA
Between January 2004 and June 2026, 900 adverse event reports received by FDA list the brand name VePesid (etoposide) as a suspect or interacting product. Reports that mention it only as a concomitant medication (190) are left out of every figure here.
In the 12 months to June 2026, 20 reports listed it, up 43% from 14 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 40 reports a year and 0% of the 20,646,523 reports in the database, and 1% of the reports for the topoisomerase inhibitor class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are off label use (9.7%), pyrexia (7.4%) and febrile neutropenia (6.8%). A report can list several reactions, so shares add to more than 100%; 275 different terms appear across these reports. Off label use is recorded in 9.7% of these reports, about the same share as in the median topoisomerase inhibitor drug (9.2%).
96.7% of the reports are marked serious by the reporter (96.8% across the class); 23.1% record death among the outcomes and 40.8% record hospitalisation, as reported. 42.8% of the reports came from other health professionals, and the largest patient age group is 45 to 64 (21.9%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of VePesid reports recording the termmedian drug in topoisomerase inhibitor
- Off label useused for a purpose or in a way not on the label9.7%87
- Pyrexiafever7.4%67
- Febrile neutropeniafever with low white blood cells6.8%61
- Neutropenialow neutrophils, a type of white blood cell5.8%52
- Sepsisa severe body-wide response to infection5.8%52
- Disease progressionthe disease advanced5.4%49
- Neoplasm progression4.9%44
- Diffuse large B-cell lymphoma refractory4.6%41
- Anaemialow red blood cells4.2%38
- Product use in unapproved indicationused for a purpose not on the label3.9%35
- White blood cell count decreasedlow white cell count3.4%31
- Bone marrow failure3.3%30
- Diarrhoealoose or frequent stools3.3%30
- Leukopenialow white blood cells3.1%28
- Product use issuea problem in how the product was used2.9%26
- Pancytopenialow counts of all blood cells2.8%25
- Thrombocytopenialow platelets2.7%24
- Mucosal inflammation2.4%22
- Platelet count decreasedlow platelet count2.3%21
- Interstitial lung diseasescarring or inflammation of lung tissue2%18
- Vomitingbeing sick2%18
- Astheniaweakness or lack of energy1.9%17
- Fatiguetiredness1.9%17
- Foetal exposure during pregnancythe unborn baby was exposed to the medicine1.9%17
- Acute myeloid leukaemia1.8%16
- Deaththe patient died; cause not stated by this term1.8%16
- Nauseafeeling sick1.8%16
- Painpain, site not specified1.8%16
- Acute kidney injurysudden loss of kidney function1.6%14
Top 30 of 275 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 12 drugs in the topoisomerase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 86,440 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 8.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Small cell lung cancer stage unspecified | 40 | 4.4% |
| Non-hodgkin's lymphoma | 26 | 2.9% |
| Non-hodgkin's lymphoma | 26 | 2.9% |
| Stem cell transplant | 26 | 2.9% |
| Lymphoma | 25 | 2.8% |
| Small cell lung cancer | 24 | 2.7% |
The indication field is filled in by the reporter and is often blank; shares are of all 900 reports.
In context
| Measure | VePesid | Topoisomerase inhibitor | All reports |
|---|---|---|---|
| Reports as suspect product | 900 | 86,440 | 20,646,523 |
| Share of that pool | — | 1% | 0% |
| Reports, latest 12 months | 20 | — | 1,332,454 |
| Marked serious | 96.7% | 96.8% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 231 | 231 | 91 |
| Hospitalisation recorded, per 1,000 reports | 408 | 362 | 213 |
| Consumer-filed share | 21.2% | 6.8% | 45.8% |
| Top term, share of reports | Off label use 9.7% | median 9.2% | 4.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the topoisomerase inhibitor class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Etoposide | generic | 62,291 | 4,749 | 97.9% |
| Irinotecan hydrochloride | generic | 6,095 | 800 | 96.6% |
| Mitoxantrone | generic | 4,065 | 132 | 98.8% |
| Topotecan | generic | 3,668 | 187 | 96.6% |
| Camptosar | brand | 2,535 | 110 | 85.4% |
| Onivyde | brand | 1,911 | 614 | 92% |
| Hycamtin | brand | 1,526 | 14 | 79.2% |
| Mitoxantrone hydrochloride | generic | 1,213 | 39 | 97.1% |
| Topotecan hydrochloride | generic | 867 | 36 | 96.8% |
| Etoposide phosphate | generic | 747 | 63 | 96.5% |
| Etopophos | brand | 622 | 8 | 84.2% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about VePesid reports
How many adverse event reports has FDA received for VePesid?
900 reports list VePesid as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 20 of them arrived in the latest 12 months. Another 190 list it only as a concomitant medication.
What reactions are recorded in VePesid reports?
off label use (9.7%), pyrexia (7.4%), febrile neutropenia (6.8%), neutropenia (5.8%) and sepsis (5.8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that VePesid was responsible.
How serious are the reports?
96.7% are marked serious by the reporter. Among the outcomes recorded, 23.1% of reports include death and 40.8% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (42.8%), physician (28.4%) and consumer or non-health professional (21.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for VePesid rising?
20 reports in the 12 months to June 2026, up 43% from 14 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that VePesid was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of VePesid?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists VePesid as a suspect or interacting product; reports listing it only as a concomitant medication (190) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.